IMATINIB MESYLATE
Generic: IMATINIB MESYLATE
Apotex CorpManufacturer
ORALRoute
IMATINIB MESYLATEActive Substance
2016-08-05Original Approval
IMATINIB MESYLATE is FDA application ANDA079179, sponsored by APOTEX. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2020-12-08
Imatinib Mesylate Tablets 400 mg, Rx Only, 30-count Bottle, Manufactured by: Shilpa Medicare Limited, India, DistributedCGMP Deviations
Class II2020-12-08
Imatinib Mesylate Tablets 100 mg, Rx Only, 90-count Bottle, Manufactured by: Shilpa Medicare Limited, India, DistributedCGMP Deviations
Top Reported Reactions
1
DRUG INEFFECTIVE
1,680 reports
2
DRUG RESISTANCE
1,059 reports
3
DEATH
1,053 reports
4
NAUSEA
1,050 reports
5
DIARRHOEA
1,045 reports
6
DRUG INTOLERANCE
931 reports
7
MALIGNANT NEOPLASM PROGRESSION
842 reports
8
FATIGUE
840 reports
9
OFF LABEL USE
795 reports
10
VOMITING
705 reports